CANSINOBIO (06185.HK) announced that the clinical trial phase II/III for its adsorbed acellular diphtheria, tetanus, and pertussis combined vaccine (Tdcp vaccine for adolescents and adults) has officially started recently, and the first subject has been recruited for the phase II clinical trial.
康希諾生物(06185.HK)Tdcp疫苗II期臨床試驗完成首例受試者入組
CANSINOBIO (06185.HK) has completed the enrollment of the first subject in the Phase II clinical trial of the Tdcp vaccine.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.